Showing results (41-50 of 313) with videos related to
Sort By:
Pageof 32
Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.Cancer|March 21, 2009
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapyRavin Garg, Hagop Kantarjian, Deborah Thomas, et al.Leukemia Research|April 12, 2003
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemiaSrdan Verstovsek, Scott Lunin, Hagop Kantarjian, et al.Cancer|January 27, 2010
Adult acute lymphoblastic leukemia: concepts and strategiesStefan Faderl, Susan O'Brien, Ching-Hon Pui, et al.Clinical Lymphoma, Myeloma & Leukemia|May 15, 2012
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalitiesYiming Chen, Hagop Kantarjian, Zeev Estrov, et al.Cancer|June 24, 2010
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimenDeborah Thomas, Susan O'Brien, Stefan Faderl, et al.Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.Leukemia & Lymphoma|August 12, 2014
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemiaUri Rozovski, Maro Ohanian, Farhad Ravandi, et al.Cancer|February 25, 2003
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.Pageof 32